Home-based medical care and concierge subscription models have moved from niche experimentation to durable growth vectors in U.S. healthcare. Demographic...
Read moreHealthcare affordability has reasserted itself as a dominant theme across employer forums, policy briefings, and financial disclosures over the past...
Read moreGLP-1 receptor agonists—marketed under brand names such as Ozempic and Wegovy—now reach an estimated one in eight American adults, according...
Read moreContinuous glucose monitors (CGMs), once reserved almost exclusively for patients with type 1 diabetes and select insulin-dependent populations, are now...
Read moreOver the past two weeks, healthcare financial discourse across earnings calls, investor notes, and sector research briefings has converged on...
Read moreGenetic testing has moved from clinical edge case to reimbursement flashpoint, and recent oversight reporting on Medicare Part B spending...
Read moreSearch and social discourse over the past two weeks show sustained, high-volume engagement around healthcare costs, medical debt, insurance denials,...
Read moreThe modern health‑insurance risk pool may be undone not by a pandemic or a demographic wave, but by a weekly...
Read moreCognitive decline has quietly become one of the most expensive line items in modern healthcare, and the bill is only...
Read moreClinical improvement and financial improvement are often assumed to move in the same direction. In healthcare payment systems, that alignment...
Read moreTransparency rules changed who asks the first question Procurement conversations historically opened with capability and differentiation. Increasingly they open with...
Read moreHospitals are not rejecting AI. They are staging it. Most large systems now maintain formal digital innovation pathways, pilot programs,...
Read moreClinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read moreDaily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.
Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.
© 2026 Daily Remedy
© 2026 Daily Remedy